Adagrasib Products | Cleanchem - Adagrasib is a targeted cancer therapy that inhibits the KRAS G12C mutation, which is common in various cancers, particularly non-small cell lung cancer (NSCLC). It works by irreversibly binding to the KRAS G12C protein, preventing its activation and disrupting the downstream signaling pathways involved in tumor growth and survival.

Adagrasib

Cat. No: CL-ADGR-001

CAS No: 2326521-71-3

Mol. F: C32H35ClFN7O2

Mol. Wt: 604.1

Inv. Status: Custom Synthesis

Adagrasib Impurity 1

Cat. No: CL-ADGR-002

CAS No: 2326521-66-6

Mol. F: C35H47FN8O2

Mol. Wt: 630.8

Inv. Status: Custom Synthesis

Adagrasib Impurity 2

Cat. No: CL-ADGR-003

CAS No: 2326524-64-3

Mol. F: C31H40BrN7O2

Mol. Wt: 622.6

Inv. Status: Custom Synthesis

Adagrasib Impurity 3

Cat. No: CL-ADGR-004

CAS No: 2326521-61-1

Mol. F: C33H37N7O3

Mol. Wt: 579.7

Inv. Status: Custom Synthesis

Adagrasib Impurity 4

Cat. No: CL-ADGR-005

CAS No: 2158302-08-8

Mol. F: C29H35N7O

Mol. Wt: 497.6

Inv. Status: Custom Synthesis

Adagrasib Impurity 5

Cat. No: CL-ADGR-006

CAS No: 2158302-07-7

Mol. F: C37H41N7O3

Mol. Wt: 631.8

Inv. Status: Custom Synthesis

Adagrasib Impurity 6

Cat. No: CL-ADGR-007

CAS No: 2326521-54-2

Mol. F: C30H38FN7O2

Mol. Wt: 547.7

Inv. Status: Custom Synthesis

Adagrasib Impurity 7

Cat. No: CL-ADGR-008

CAS No: 2375588-99-9

Mol. F: C29H32ClFN6O3S

Mol. Wt: 599.1

Inv. Status: Custom Synthesis

Adagrasib Impurity 8

Cat. No: CL-ADGR-009

CAS No: 2206737-09-7

Mol. F: C32H45N7O3

Mol. Wt: 575.8

Inv. Status: Custom Synthesis

Adagrasib Impurity 9

Cat. No: CL-ADGR-010

CAS No: 2206737-07-5

Mol. F: C27H37N7O

Mol. Wt: 475.6

Inv. Status: Custom Synthesis

Adagrasib Impurity 10

Cat. No: CL-ADGR-011

CAS No: NA

Mol. F: C29H34ClN7O

Mol. Wt: 532.1

Inv. Status: Custom Synthesis

Adagrasib Impurity 11

Cat. No: CL-ADGR-012

CAS No: 791828-58-5

Mol. F: C21H28N4O5

Mol. Wt: 416.5

Inv. Status: Custom Synthesis